Tomivosertib (eFT-508)
Phase 2Completed 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Solid Tumors
Conditions
Solid Tumors
Trial Timeline
Jul 25, 2018 → Jun 30, 2021
NCT ID
NCT03616834About Tomivosertib (eFT-508)
Tomivosertib (eFT-508) is a phase 2 stage product being developed by eFFECTOR Therapeutics for Solid Tumors. The current trial status is completed. This product is registered under clinical trial identifier NCT03616834. Target conditions include Solid Tumors.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03616834 | Phase 2 | Completed |
| NCT02937675 | Phase 1/2 | Terminated |
Competing Products
20 competing products in Solid Tumors